Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Bone and Hormonal Milieu: Implications for Adjuvant Therapy

Release Date: March 26, 2009| Expiration Date: March 26, 2010
0.75 AMA PRA Category 1 Credit(s)™| Mar 6, 2009, Miami, FL

Lecture Overview

For patients with hormone receptor–positive early-stage breast cancer, both tamoxifen and aromatase inhibitors have dramatically improved disease outcome. However, significant risk of recurrence continues to persist long after completion of adjuvant endocrine therapy, suggesting that there is room for improvement in this area of breast cancer therapy. Recent recommendations suggest inclusion of an aromatase inhibitor at some point in the adjuvant treatment regimen for postmenopausal patients, although the optimal timing and duration of this therapy is still controversial. Additionally, bone complications present a frequent clinical challenge for patients with breast cancer. Many therapies used in treating patients with early-stage breast cancer can have a deleterious effect on bone density, leading to increased risk of fracture, requiring physicians to monitor the bone health status of their patients and be knowledgeable about optimal therapeutic strategies. Finally, bone-targeted agents might also have a direct effect on tumors, and several studies have suggested these agents might have utility in reducing the risk of metastases and disease progression. The Bone and Hormonal Milieu: Implications for Adjuvant Therapy symposium is designed to update physicians on the latest information regarding the safety and efficacy of hormonal therapies and bone-targeted therapies for early-stage breast cancer.

This educational program is directed toward medical oncologists, surgeons, and radiation oncologists interested in the treatment of breast cancer. Physician assistants, research nurses, and fellows interested in the treatment of patients with breast cancer are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Evaluate the use of bone-targeted agents for the prevention of treatment-induced bone loss and the prevention of bone metastases in patients with early-stage breast cancer
  • Review the latest clinical data on adjuvant endocrine therapy, including up-front compared to switching strategies and extended therapy with selective estrogen receptor modulators and aromatase inhibitors
  • Apply data from clinical trials and consensus guidelines to optimize choices concerning endocrine therapy and the management of bone health in early-stage breast cancer in defined clinical situations

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Complete the test(s) and evaluation by March 26, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from The Bone and Hormonal Milieu: Implications for Adjuvant Therapy symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Hope S. Rugo, MD
Research Funding – Abbott Laboratories, Abraxis Bioscience, LLC, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.; Speaker’s Bureau – AstraZeneca, Genomic Health, Inc.

Hyman B. Muss, MD
Research Funding – AstraZeneca, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.; Paid Consultant – Amgen, Bristol-Myers Squibb Company, Genentech, Inc., Pfizer Inc., Roche Pharmaceuticals, Tragara Pharmaceuticals Inc.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2009 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, The Bone and Hormonal Milieu: Implications for Adjuvant Therapy
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology